- Home
- KRC vs TNGX Comparison
KRC vs TNGX Comparison
Compare KRC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | TNGX |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRC | TNGX |
|---|---|---|
| Price | $33.44 | $23.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $37.36 | $21.78 |
| AVG Volume (30 Days) | 2.2M | ★ 2.9M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.57% | N/A |
| EPS Growth | ★ 31.07 | 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,112,667,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $27.36 | $1.04 |
| 52 Week High | $45.03 | $28.41 |
Technical Indicators
Market Signals| Indicator | KRC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 65.32 | 52.39 |
| Support Level | $27.63 | $6.83 |
| Resistance Level | $35.06 | $28.41 |
| Average True Range (ATR) | 0.97 | 1.83 |
| MACD | 0.29 | -0.69 |
| Stochastic Oscillator | 81.59 | 32.29 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.